Trial · NCT04854811
Roflumilast to Treat Cognitive Sequela After Stroke
NCT04854811, Phase 2, Completed, Maastricht University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Roflumilast to Treat Cognitive Sequela After Stroke. Trials, record NCT04854811. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04854811
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Roflumilast to Treat Cognitive Sequela After Stroke
- NCT number
- NCT04854811
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 100 participants, actual
- Lead sponsor
- Maastricht University
- Conditions
- Cerebrovascular Disorders, Memory, Functional Recovery, Drug Intervention
- Interventions
- Roflumilast Oral Tablet
- First posted
- 2021-04-22
- Last updated
- 2024-01-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Verbal Learning Test (VLT) Verbal Learning Test (VLT) (15 words) (delayed recall) [ Time Frame: Change from baseline to 12 weeks of chronic intake ] Verbal Learning Test (VLT) | Change from baseline to 12 weeks of chronic intake | 15 words, delayed recall |
| Secondary | Verbal Learning Test (VLT) | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) | 15 words, delayed recall |
| Secondary | Rivermead Behavioural Memory Test | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) | |
| Secondary | Digit Symbol Substitution Test (DSST) | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) | |
| Secondary | Trail Making Test (TMT) | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) | |
| Secondary | Everyday Memory Questionnaire | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) | |
| Secondary | the total mood score of the Hospital Anxiety and Depression Scale questionnaire (HADS) | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) | |
| Secondary | Mood and well-being: Utrecht Scale for Evaluation of Rehabilitation-Participation (USER-Participation) (USER-P) | Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Verbal Learning | Primary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04854811
GET https://conductscience.org/api/trials/v1/NCT04854811/registered